文献速递胸部肿瘤

从不吸烟者肺腺癌的基因组图谱分析

Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
PubMed 文献 · J Clin Oncol · 2021-09-30

该研究对160例从不吸烟者肺腺癌样本进行全外显子组和RNA测序,并与TCGA及CPTAC数据中76例从不吸烟者和299例吸烟者样本联合分析。从不吸烟者肺腺癌中临床可操作驱动基因改变的发生率高达78%-92%,显著高于吸烟者的49.5%(P < .0001);部分从不吸烟者样本存在DNA修复基因胚系变异及提示被动吸烟的突变特征。

要点

  • 从不吸烟者肺腺癌临床可操作驱动改变比例高(78%-92% vs 49.5%,P < .0001),应重视活检细胞量以行基因组检测。
  • 从不吸烟者与吸烟者肿瘤易感基因胚系变异频率相当(6.4% vs 6.9%,P = .82)。
  • 从不吸烟者肺腺癌存在提示被动吸烟的突变特征及不同免疫转录亚型。

核心结论

  • 从不吸烟者肺腺癌中临床可操作驱动基因改变高度流行,支持对该人群进行充分活检以开展临床基因组检测。
  • DNA修复基因胚系变异和被动吸烟可能在部分从不吸烟者肺腺癌的发病中起作用。
  • 从不吸烟者肺腺癌存在表达临床相关免疫检查点分子及免疫细胞组成各异的免疫转录亚型。

研究设计与样本

  • 对160例从不吸烟者肺腺癌的肿瘤与正常肺组织进行全外显子组和RNA测序,其中88例和69例分别完成全外显子组和RNA测序。
  • 联合分析TCGA和CPTAC的76例从不吸烟者和299例吸烟者肺腺癌测序数据。
  • 研究为基因组与转录组分析,非干预性研究。

主要发现

  • 从不吸烟者肺腺癌临床可操作驱动改变发生率为78%-92%,吸烟者为49.5%(P < .0001)。
  • 从不吸烟者与吸烟者肿瘤易感基因胚系变异频率分别为6.4%和6.9%(P = .82)。
  • 5.9%的从不吸烟者样本显示提示被动吸烟的突变特征。
  • RNA测序分析显示从不吸烟者肺腺癌具有不同的免疫转录亚型。

临床怎么用

  • 对从不吸烟者肺腺癌患者应确保活检标本有足够细胞量以完成临床基因组检测。
  • 可关注DNA修复基因胚系变异及被动吸烟暴露史在从不吸烟者肺腺癌风险评估中的潜在意义。
  • 免疫转录亚型差异可能为免疫治疗决策提供参考,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Approximately 10%-40% of patients with lung cancer report no history of tobacco smoking (never-smokers). We analyzed whole-exome and RNA-sequencing data of 160 tumor and normal lung adenocarcinoma (LUAD) samples from never-smokers to identify clinically actionable alterations and gain insight into the environmental and hereditary risk factors for LUAD among never-smokers. METHODS: We performed whole-exome and RNA-sequencing of 88 and 69 never-smoker LUADs. We analyzed these data in conjunction with data from 76 never-smoker and 299 smoker LUAD samples sequenced by The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium. RESULTS: We observed a high prevalence of clinically actionable driver alterations in never-smoker LUADs compared with smoker LUADs (78%-92% v 49.5%; P < .0001). Although a subset of never-smoker samples demonstrated germline alterations in DNA repair genes, the frequency of samples showing germline variants in cancer predisposing genes was comparable between smokers and never-smokers (6.4% v 6.9%; P = .82). A subset of never-smoker samples (5.9%) showed mutation signatures that were suggestive of passive exposure to cigarette smoke. Finally, analysis of RNA-sequencing data showed distinct immune transcriptional subtypes of never-smoker LUADs that varied in their expression of clinically relevant immune checkpoint molecules and immune cell composition. CONCLUSION: In this comprehensive genomic and transcriptome analysis of never-smoker LUADs, we observed a potential role for germline variants in DNA repair genes and passive exposure to cigarette smoke in the pathogenesis of a subset of never-smoker LUADs. Our findings also show that clinically actionable driver alterations are highly prevalent in never-smoker LUADs, highlighting the need for obtaining biopsies with adequate cellularity for clinical genomic testing in these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Devarakonda S, Li Y, Martins Rodrigues F, et al. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. J Clin Oncol. 2021. PMID: 34591593. doi:10.1200/JCO.21.01691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。